知镜 Cognispect · 医学文献与研究工作台

Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity.

Osman MM, Sims OT, Chiang DJ.
Annals of hepatology · 2026-10-23 · PMID 42913941

文献摘要

Introduction and objectives Sodium-glucose co-transporter 2 inhibitors (SGLT2-i 1 ) improve cardiovascular and renal outcomes in type 2 diabetes mellitus, but their safety and clinical impact in advanced liver disease remain uncertain because patients with cirrhosis were underrepresented in major trials. Materials and methods Using the TriNetX research network, we identified adults with alcoholic cirrhosis, type 2 diabetes, and obesity and compared outcomes according to SGLT2-i exposure. After 1:1 propensity score matching, 5,128 matched pairs were analyzed. The primary outcome was all-cause mortality; secondary outcomes included all-cause hospitalization, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and variceal bleeding. Results In the matched cohort, SGLT2-i use was associated with lower all-cause mortality (HR, 0.71; 95% CI, 0.66 to 0.78), hospitalization (HR, 0.84; 95% CI, 0.80 to 0.89), ascites (HR, 0.72; 95% CI, 0.67 to 0.77), spontaneous bacterial peritonitis (HR, 0.74; 95% CI, 0.62 to 0.87), and variceal bleeding (HR, 0.82; 95% CI, 0.67 to 0.99), with no difference in hepatic encephalopathy. Conclusions Among patients with alcoholic cirrhosis, type 2 diabetes, and obesity, SGLT2-i use was associated with improved survival and fewer liver-related complications.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。